Showing 5191-5200 of 7761 results for "".
- TSLMS Announces New Name for its Meeting: Symposium for Cosmetic Advances and Laser Educationhttps://practicaldermatology.com/news/20131001-tslms_announces_new_name_for_its_meeting_symposium_for_cosmetic_advances_and_laser_education/2459447/The Tennessee Society for Laser Medicine & Surgery (TSLMS) announced that its 9th annual meeting Feb. 22-Mar. 2, 2014. The TSLMS introduced
- KYTHERA Announces Positive ATX-101 Top Line Phase III Trial Resultshttps://practicaldermatology.com/news/20130925-kythera_announces_positive_atx-101_top_line_phase_iii_trial_results/2459452/KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH) today announced that its ATX-101 REFINE-1 and REFINE-2 Phase III trials met all primary and secondary endpoints. These two pivotal Phase III trials were conducted in the U.S. and Canada to compare the efficacy and safety of a 2 mg/cm2 dose of ATX-101 v
- Nucletron Introduces Esteya Electronic Brachytherapy for Treating Skin Cancerhttps://practicaldermatology.com/news/20130923-nucletron_introduces_esteya_electronic_brachytherapy_for_treating_skin_cancer/2459456/Nucletron, an Elekta company, recently launched Esteya, a new approach for treating patients with skin cancer. Esteya electronic brachytherapy mimics proven high dose rate (HDR) brachytherapy by bringing a small X-ray source very close to the cancerous site, enabling the local a
- Stelara Receives FDA Approval To Treat Active Psoriatic Arthritishttps://practicaldermatology.com/news/20130923-stelara_receives_fda_approval_to_treat_active_psoriatic_arthritis/2459457/The FDA recently approved Stelara (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis. For the treatment of psoriatic arthritis, Stelara is administered as a 45
- GSK Receives FDA Priority Review for Dabrafenib/Trametinib Combination in Metastatic Melanomahttps://practicaldermatology.com/news/20130916-gsk_receives_priority_review_from_fda_for_dabrafenibtrametinib_combination_in_metastatic_melanoma/2459460/The FDA has granted priority review designation to GlaxoSmithKline's supplemental New Drug Applications (sNDAs) for combined use of Tafinlar (dabrafenib) and Mekinist (trametinib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 E or
- FDA Approves Botox Cosmetic to Treat Crow's Feet Lines in Adultshttps://practicaldermatology.com/news/20130912-fda_approves_botox_cosmetic_to_treat_crows_feet_lines_in_adults/2459463/The FDA recently approved Botox Cosmetic (onabotulinumtoxinA) for an additional indication to temporarily treat moderate to severe lateral canthal lines. Allergan's
- Anacor Submits NDA, Presents Data for Tavaborolehttps://practicaldermatology.com/news/20130830-anacor_submits_nda_presents_data_for_tavaborole/2459469/Anacor Pharmaceuticals has submitted an NDA to the FDA for for Tavaborole, its drug candidate for the topical treatment of onychomycosis. The company recently reported data presented at this summer's 2013 APMA Annual Scientific Meeting. Findings s
- FDA Approves Mirvaso for Treating Facial Erythema of Rosaceahttps://practicaldermatology.com/news/20130826-fda_approves_mirvaso_for_treating_facial_erythema_of_rosacea/2459476/The FDA recently approved Mirvaso (brimonidine) gel, 0.33% for the topical treatment of the facial erythema of rosacea in adults 18 years of age or older. According to manufacturer Galderma Laboratories, applied once
- Alphaeon Acquires US License To Teoxane Laboratories' Dermal Fillers And Cosmeceutical Productshttps://practicaldermatology.com/news/20130802-alphaeon_acquires_us_license_to_teoxane_laboratories_dermal_fillers_and_cosmeceutical_products/2459484/Alphaeon Corporation, a wholly-owned subsidiary of Strathspey Crown Holdings, LLC, has acquired an exclusive US license for the full line of products from Teoxane Laboratories. Containing 100 percent non-animal origin, resorbable hyaluronic acid, Teoxane's dermal fillers are currently available in m
- LEO Launches Taclonex in Larger Package Sizehttps://practicaldermatology.com/news/20130730-leo_launches_taclonex_in_larger_package_size/2459488/LEO Pharma Inc., has launched a patient-friendly 120g package size of Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of plaque psoriasis.